Skip to main content
. 2024 Feb 25;15(8):2206–2213. doi: 10.7150/jca.92656

Table 2.

Prognostic value of KIF-12 in d-THCA

Characteristics Total (N) HR (95% CI) Univariate analysis P value Univariate analysis HR (95% CI) Multivariate analysis P value Multivariate analysis
T stage (T3&T4 vs. T1&T2) 500 2.507(1.434-4.385) 0.001 0.752(0.181-3.115) 0.694
N stage (N1 vs. N0) 452 1.578(0.885-2.814) 0.122
M stage (M1 vs. M0) 291 7.542(2.860-19.891) <0.001 6.818(2.103-22.106) 0.001
Pathologic stage (Stage III & Stage IV vs. Stage I & Stage II) 500 2.615(1.515-4.515) <0.001 2.712(0.811-9.068) 0.105
Residual tumour (R1&R2 vs. R0) 440 1.773(0.856-3.674) 0.123
Histological type (Classical vs. Follicular & Other & Tall Cell) 502 1.022(0.553-1.888) 0.944
Age (>45 vs. <=45) 502 1.618(0.924-2.834) 0.092 1.109(0.370-3.323) 0.853
Sex (Male vs. Female) 502 1.529(0.863-2.709) 0.146
Race (White vs. Asian & Black or African American) 410 1.183(0.529-2.646) 0.682
Neoplasm location (Bilateral vs. Isthmus & Left lobe & Right lobe) 496 1.150(0.558-2.370) 0.704
Primary neoplasm focus type (Multifocal vs. Unifocal) 492 1.036(0.595-1.802) 0.901
Thyroid gland disorder history (Lymphocytic Thyroiditis & Nodular Hyperplasia & Other, specify vs. Normal) 444 0.966(0.520-1.795) 0.913
Extrathyroidal extension (Yes vs. No) 484 1.995(1.151-3.458) 0.014 1.054(0.303-3.663) 0.935
BRAF status (Mut vs. WT) 485 1.266(0.703-2.280) 0.432
NRAS status (Mut vs. WT) 485 1.958(0.830-4.615) 0.125
HRAS status (Mut vs. WT) 485 1.033(0.251-4.258) 0.964
KIF12 (High vs. Low) 502 0.431(0.239-0.777) 0.005 0.319(0.130-0.784) 0.013